Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy
Status:
Completed
Trial end date:
2015-08-24
Target enrollment:
Participant gender:
Summary
This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding
Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric
Hypertrophy.
Phase:
Phase 2
Details
Lead Sponsor:
Medy-Tox
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA